Enhanced Parkinson's Care
Parkinson's Disease
Key Facts
About Navamedic
Navamedic's mission is to be a reliable supplier of high-quality pharmaceutical products and medical nutrition, focusing on niche therapeutic areas with unmet needs. The company has achieved consistent growth, reporting 2025 revenue of MNOK 565.4 and a profitable EBITDA of MNOK 47.6, supported by a portfolio of ~50 brands. Its strategy centers on a capital-efficient, commercial-stage model: in-licensing or acquiring approved or near-approved products, then leveraging its established Nordic regulatory, distribution, and market access expertise for launch and lifecycle management. A key strategic pillar is building deep patient community relationships, exemplified by its 'In Good Company' support program for metabolic diseases.
View full company profileTherapeutic Areas
Other Parkinson's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| NPT200-11 | Neuropore Therapies | Phase 1 |
| VXX-301 | Vaxxinity | Preclinical |
| BAN2802 | BioArctic | Phase 1 |
| CNM-Au8 | Clene | Phase 2 |
| hpSC-Derived Neural/Dopaminergic Cells | International Stem Cell | Preclinical/Early Clinical |
| SLS-004 | Seelos Therapeutics | Preclinical |
| SLS-007 | Seelos Therapeutics | Preclinical |
| Parkinson's Disease Research | ProgenaBiome | Research |
| A9 Dopaminergic Neuron Therapy | Trailhead Biosystems | Pre-clinical |
| golexanolone | Umecrine Cognition | Preclinical |
| Bezisterim (NE3107) | BioVie | Phase 2 |
| Cannabinoid-based Therapy | Gb Sciences | Preclinical |